Andere talen Cingulate Inc.

Aandelen

CING

US17248W2044

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,586 ^USD	-3,46%		+2,81%	-92,34%

21/05	FDA geeft Cingulate toestemming om CTx-1301 in te dienen voor de behandeling van ADHD	CI
08/05	Cingulate Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event	25/06
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance	25/06
Cingulate : Failure to Satisfy Listing Rule Form 8 K	19/06
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD	21/05
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD	21/05
Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update	08/05
Certain Pre-Funded Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Certain Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Certain Stock Options of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Certain Common Stock of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access	30/04
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024	16/04
Cingulate Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Cingulate Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update	01/04
Cingulate to Participate in Benzinga All Live Access Event	19/03
Cingulate to Attend DCAT Week 2024 in New York City	06/03
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors	13/02
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors	13/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cingulate Inc.

Aandelen

CING

US17248W2044

Andere talen

Filters